Outcomes following bail-out abciximab administration during primary intervention in acute myocardial infarction (The CADILLAC Trial)

Dale T Ashby; Eve A Aymong; James E Tcheng; Cindy L Grines; David A Cox; Roxana Mehran; Eulogio Garcia; John J Griffin; Giulio Guagliumi; Thomas Stuckey; Mark Turco; Alexandra J Lansky; Gregg W Stone; CADILLAC Trial

doi:10.1016/j.amjcard.2003.06.005

Outcomes following bail-out abciximab administration during primary intervention in acute myocardial infarction (The CADILLAC Trial)

Am J Cardiol. 2003 Nov 1;92(9):1091-4. doi: 10.1016/j.amjcard.2003.06.005.

Authors

Dale T Ashby¹, Eve A Aymong, James E Tcheng, Cindy L Grines, David A Cox, Roxana Mehran, Eulogio Garcia, John J Griffin, Giulio Guagliumi, Thomas Stuckey, Mark Turco, Alexandra J Lansky, Gregg W Stone; CADILLAC Trial

Affiliation

¹ Cardiovascular Research Foundation and Lenox Hill Heart and Vascular Institute, New York City, New York 10022, USA.

PMID: 14583362
DOI: 10.1016/j.amjcard.2003.06.005

Abstract

The utility of glycoprotein IIb/IIIa receptor inhibitors as a "bail-out" modality after unsuccessful primary percutaneous coronary intervention for acute myocardial infarction is unknown. In the CADILLAC trial, of 1,030 control patients, 62 patients (6.0%) crossed over and received abciximab for procedural complications or suboptimal angioplasty results. Compared with patients who received routine upfront abciximab, those treated with bail-out abciximab had markedly lower rates of Thrombolysis In Myocardial Infarction grade 3 flow and increased rates of hemorrhagic and ischemic complications at 30 days and 1 year.

Publication types

Clinical Trial
Multicenter Study
Randomized Controlled Trial

MeSH terms

Abciximab
Aged
Angioplasty, Balloon, Coronary*
Antibodies, Monoclonal / administration & dosage*
Cross-Over Studies
Drug Administration Schedule
Female
Follow-Up Studies
Humans
Immunoglobulin Fab Fragments / administration & dosage*
Intraoperative Complications*
Male
Middle Aged
Myocardial Infarction / mortality
Myocardial Infarction / therapy*
Platelet Glycoprotein GPIIb-IIIa Complex / administration & dosage*
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*
Prospective Studies
Treatment Failure

Substances

Antibodies, Monoclonal
Immunoglobulin Fab Fragments
Platelet Glycoprotein GPIIb-IIIa Complex
Abciximab